Trial Profile
A Phase II Study of Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma: Hoosier Oncology Group LYM08-134.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 27 Oct 2016
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Fludarabine (Primary) ; Rituximab (Primary)
- Indications Follicular lymphoma
- Focus Therapeutic Use
- 06 Sep 2010 New trial record